U.S. Online Retail and Ecommerce Stock News

Curious if Four Corners Property Trust is a bargain or too pricey in today’s market? Let’s break down what’s driving the stock’s value and whether there’s opportunity ahead. Even though the stock slipped 0.1% over the past week and 1.8% in the last 30 days, it is only down 9.8% in the past year, showing signs of resilience amidst a tough environment. Investors have been keeping an eye on rising interest rates and evolving commercial real estate trends, both of which continue to influence...

If you have ever wondered whether Vertex stock is trading at a bargain or an inflated price, you are in the right place for some answers. After a rough few months, Vertex shares have dropped by 20.7% over the last week and are down 54.4% over the past year, suggesting a dramatic shift in market sentiment around the company. Much of this decline has been set against a backdrop of challenging headlines, including industry-wide volatility in the software sector, as well as broader market...

Premier (PINC) reported a net profit margin of just 0.7% this quarter, a sharp drop from last year’s 11.2%, with earnings having declined at an average annual rate of -25.5% over the past five years. Despite recent pressures, the company is now profitable and is forecasting a robust 32.6% annual earnings growth over the next three years, which is double the 16% expected for the US market overall. These mixed results, combined with a one-off $162.9 million loss, have pushed Premier’s shares to...

Kura Oncology (KURA) remains unprofitable and is projected to stay in the red for at least the next three years, with losses having widened at a pace of 15.3% per year over the last five. Despite negative profit margins and no signs of bottom-line improvement, the company is forecast to deliver revenue growth of 42.7% annually, significantly outpacing the broader US market’s 10.5% revenue growth expectation. Investors now face a trade-off between robust top-line growth potential and the...

ONE Gas (OGS) reported net profit margins of 10.8%, slightly ahead of last year’s 10.5%, as annual earnings growth reached 17.7%, substantially outpacing the company’s five-year average of 4.5%. Earnings are forecast to grow at 8.94% per year, but both profit and revenue trends remain below broader US market averages. Investors will note that despite stronger bottom-line results, valuation appears mixed given that the stock’s Price-to-Earnings ratio sits between its US and global gas utility...

Harmony Biosciences Holdings (HRMY) delivered a net profit margin of 22.5% this period, well above last year's 18%. Earnings grew by 51.4% over the past year, outpacing both its own five-year average growth rate of 40.8% and broader US market expectations. Looking ahead, analysts forecast earnings to grow 20.5% per year, surpassing the US market's 16%, while revenue is expected to rise at 12.7% annually compared to the market's 10.5% pace. This combination of sustained profitability and...

On November 3, 2025, Prelude Therapeutics announced a private placement, raising US$25,000,000 by issuing 6,250,000 shares at US$4 each, with participation from Incyte Corporation. Institutional interest from a company like Incyte can be viewed as an endorsement of Prelude’s research direction and funding outlook. We’ll explore how Incyte’s involvement in the private placement shapes Prelude’s investment narrative and financial flexibility. The best AI stocks today may lie beyond giants like...

Expeditors International of Washington (EXPD) reported a net profit margin of 7.6%, up from 7.4% a year ago, signaling a modest expansion in profitability. Earnings grew 15.4% over the past year. However, the longer-term five-year trend shows a decline of 6% per year. Looking ahead, analysts expect earnings to decline by 1.1% annually over the next three years, along with minimal revenue growth of 0.2% per year. This trails well behind the broader US market's projected 10.5% annual rate. The...

Wondering if StepStone Group is a hidden gem or getting pricey? You are not alone, and we're here to break down the numbers in plain English. The stock has seen returns of 5.4% year-to-date and 5.9% over the last year, despite minor pullbacks in the last week and month. StepStone's share price has been influenced by recent headlines detailing its continued expansion in private markets and new fund launches, which have caught the eye of both industry watchers and investors. This activity has...

Better Home & Finance (BETR) is in the spotlight after activist investor Eric Jackson endorsed the company for its ability to transform the mortgage sector using AI and digital technologies. Jackson drew comparisons to top e-commerce innovators. See our latest analysis for Better Home & Finance Holding. Shares of Better Home & Finance have been on a tear, climbing a remarkable 609.96% year-to-date in terms of share price return, with explosive momentum particularly in the last quarter. While...

First Watch Restaurant Group (FWRG) reported a net profit margin of 0.4% this quarter, slipping from 2.1% last year as margins tightened. While a $2.5 million one-off loss weighed on trailing results and short-term earnings growth was negative, the company has turned profitable over the last five years with robust compound growth. Despite mixed financial signals, investors are taking note of optimistic forecasts, with earnings expected to climb 39.3% annually over the next three years, well...

Spotify Technology (SPOT) delivered standout results this earnings season, with net profit margins reaching 8.3%, up sharply from 4.6% previously, and EPS growth an impressive 100.4% year-over-year compared to its 5-year average of 56% per year. The company’s forward guidance calls for continued momentum, forecasting annual EPS growth of 26.8% and revenue growth of 12%, both outpacing the broader US market. With current profitability trends and no major risks identified in the latest filings,...

SunCoke Energy (SXC) faces a tough road ahead, with earnings projected to decline by 2.3% per year and revenue expected to contract at an even sharper rate of 8.5% annually over the next three years. The company’s net profit margin has slipped to 3.5%, down from 4.4% the year before, reflecting a negative turn in recent profitability after five years of strong average annual profit growth. As a result, investors are likely viewing SunCoke’s earnings update as a move from years of expansion...

Gladstone Commercial (GOOD) is forecasting earnings growth of 20.6% per year, outpacing the US market’s expected 16% annual growth rate. Over the last five years, the company’s earnings have grown at an impressive average rate of 41.7% each year, and earnings quality remains high. Revenue growth is projected at 5.5% per year, trailing the broader US market average of 10.5%. Net profit margin stands at 5.4%, just below last year’s 5.7%. With shares currently trading at $10.7, below both...

Coterra Energy (CTRA) reported earnings that accelerated 33% over the past year, outpacing the company’s five-year average growth of 11.5% per year. Net profit margins improved from 23.4% to 24.4%, indicating stronger profitability. With earnings forecast to grow at 10.63% annually and revenue also projected to advance by about 10% each year, investors have reason to be optimistic about continued performance momentum. See our full analysis for Coterra Energy. Next, we will see how these...

Sequans Communications (SQNS) is currently unprofitable, but has managed to reduce losses by 42.6% per year over the past five years. Revenue is expected to grow 25.61% annually, well ahead of the US market average growth rate of 10.5%. However, the company is still forecast to remain in the red over the next three years. Investors looking at the setup will see attractive top-line growth prospects and a price-to-sales ratio of 2.7x, which is notably lower than the semiconductor industry...

Caribou Biosciences (CRBU) is attracting fresh attention after releasing positive interim data from phase 1 trials of its lead CAR-T therapies, vispacabtagene regedleucel and CB-011, for lymphoma and multiple myeloma. See our latest analysis for Caribou Biosciences. Momentum has picked up for Caribou Biosciences following its positive clinical trial updates and upcoming pivotal studies, but recent volatility is hard to ignore. The stock’s 1-day share price return dropped 10.7% after the data...

Compass (COMP) remains unprofitable, but over the last five years the company has steadily narrowed its losses by an average of 21.1% each year. Looking forward, earnings are forecast to grow at a rapid 61.21% per year, with analysts expecting Compass to reach profitability within the next three years. With annual revenue projected to grow at 10.8%, outpacing the broader US market’s 10.5% estimate, the equity story for Compass is tilted toward rewards due to anticipated strong profit and...

Wondering if TriMas is trading for less than it's worth? You're not alone, as investors are always keen to spot undervalued opportunities before the market catches on. TriMas has seen some sharp moves lately, with the stock dropping 11.1% over the last week and 10.7% in the past month, even though it's still up 41.3% year-to-date. Market watchers are buzzing about recent industry developments and shifting economic conditions that are shining a spotlight on companies like TriMas. These...

Genius Sports (GENI) continues to operate at a loss, but over the last five years, it has managed to cut annual losses by 26%. While the company remains unprofitable, analysts project impressive earnings growth of 100.48% per year and expect profitability within three years. With revenue forecast to climb 15% annually, which is higher than the broader US market forecast of 10.5%, investors have a front-row seat to a transition story fueled by rapid top-line expectations and progressively...

CompoSecure (CMPO) remains unprofitable, with net losses deepening at a rate of 66.8% per year over the past five years. Still, analysts forecast earnings to grow 168.7% annually and expect the company to cross into profitability within the next three years. Revenue is projected to climb 37.6% a year, which far outpaces the US market average of 10.5%. See our full analysis for CompoSecure. The next section examines how these headline numbers align with well-known market narratives,...

Denny's (DENN) net profit margin slipped to 2.2% from last year's 3.9%, with annual earnings declining by 11.9% over the past five years and recent negative growth that makes year-on-year comparisons tough. Investors may be watching closely as revenue is only expected to grow at 3.4% per year, lagging well behind the broader US market’s projected 10.5%. However, despite these lackluster trends and a relatively rich valuation, forecasts are calling for a sharp rebound in earnings, with a...

Norwegian Cruise Line Holdings (NCLH) posted net profit margins of 6.8%, up from 5.9% last year, showing clear margin improvement. Earnings have grown rapidly at 59.2% per year over the past five years. Forward-looking estimates see earnings increasing another 37.9% per year. Even as this outpaces the broader US market, revenue growth forecasts of 8.6% per year trail the US average of 10.5%. While investors will note a recent one-off loss of $272.5 million that hit results, the stock looks...

Kymera Therapeutics (KYMR) posted another unprofitable year, with annual losses growing at a rate of 28.4% per year over the past five years. The company’s margins remain under pressure, and analysts expect revenue to contract by roughly 2.5% annually over the next three years. Shares are currently trading at $59.91. With profitability still out of reach and revenue momentum fading, the numbers highlight the continued financial headwinds for Kymera. See our full analysis for Kymera...